



Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events

BERKELEY HEIGHTS, N.J., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced certain corporate events that will take place during November and December 2011.

Release of 3Q11 Financial Results and Conference Call — Monday, November 14

Cyclacel will announce its third quarter 2011 financial results on Monday, November 14, 2011. The Company will host a conference call and webcast at 4:30 PM Eastern Time that day to review these results as well as Cyclacel's clinical development programs.

Conference call information:

US/Canada call: (877) 493-9121 / international call: (973) 582-2750

US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406

Code for live and archived conference call is 25156473

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

Lazard Capital Markets 8th Annual Healthcare Conference — Tuesday, November 15

Spiro Rombotis, President and Chief Executive Officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference at The Pierre Hotel in New York City. Cyclacel's presentation will take place on Tuesday, November 15 at 11:00 AM Eastern Time.

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

53rd Annual Meeting of the American Society of Hematology (ASH) — Monday, December 12

An abstract regarding sapacitabine has been accepted as a poster presentation during the 53rd Annual Meeting of ASH in San Diego, CA on Monday, December 12, 2011. The poster's abstract details are as follows:

Abstract: 3630

Title: Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML

Date/Time: Monday, December 12, 2011, 6:00 PM — 8:00 PM Pacific Time
San Diego Convention Center, Hall GH

Session: 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster III

In accordance with the ASH Annual Meeting Embargo Policy, abstracts selected for the 2011 annual meeting will be made public online at 10:00 AM Eastern Time on November 7, 2011 in compliance with the Securities and Exchange Commission's Regulation FD. These abstracts will also be published in a special Abstract Book issue of Blood, around the middle of November 2011. For more information please refer to: <http://www.hematology.org/Meetings/Annual-Meeting/3734.aspx>.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), an orally-available, cell cycle modulating, nucleoside analogue, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia. Seliciclib (CYC202 or R-roscovitine), an orally-available, CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

© Copyright 2011 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn® and Xclair® are trademarks of Sinclair Pharma plc.

CONTACT: Investors/Media: Corey Sohmer,

(908) 517-7330, csohmer@cyclacel.com